Benefits
Blood pressure reduction in Grade-1 hypertension
In 77 Grade-1 hypertensive patients receiving prescribed BP medication, ABG10+ at 250 mg/day over 12 weeks produced significant reductions in systolic (1.8 mmHg) and diastolic (1.5 mmHg) blood pressure vs placebo. The reductions occurred ON top of standard antihypertensive drug therapy — supporting use as a complementary intervention rather than a replacement for prescribed BP medications.
Diastolic BP reduction in hypercholesterolemia
A separate 2022 clinical trial in participants with moderately elevated cholesterol levels documented significant reduction in diastolic blood pressure of 5.85 mmHg on average vs placebo. The effect size in this population was larger than in the Grade-1 hypertension trial — suggesting ABG10+ may produce greater BP effects in adults with metabolic risk factors beyond hypertension alone.
Nitric oxide enhancement
Blood serum tests in the hypertension trial showed ABG10+ supplementation may enhance nitric oxide (NO) release. NO is a natural vasorelaxant produced in the body to maintain cardiovascular function — improving blood pressure and increasing blood flow. NO also serves as a cellular antioxidant. Mechanism complements direct BP effects with broader vascular health support.
ACE activity reduction
ABG10+ supplementation decreased angiotensin-converting enzyme (ACE) activity in trial participants. ACE inhibition is a key pharmaceutical strategy for blood pressure reduction — used by ACE inhibitor drugs (lisinopril, enalapril). ABG10+ provides natural ACE modulation, explaining part of its BP-lowering mechanism through the same pathway as conventional medications, though milder in magnitude.
HDL functionality improvement
A 2026 medRxiv preprint analyzed lipoprotein subclasses by NMR spectroscopy in 75 Grade-1 hypertensive participants taking 250 mg ABG10+ over 12 weeks. Large HDL particles exhibited beneficial remodeling — increased phospholipid content and decreased triglyceride percentage. These qualitative HDL changes may provide cardiovascular benefit beyond what total HDL cholesterol measurement reveals.
VLDL cholesterol load reduction
The same lipoprotein subclass analysis showed reductions in cholesterol load (both free and esterified) in XXL-VLDL particles with ABG10+ supplementation. Reduced large VLDL cholesterol content may provide cardiovascular benefits in hypertensive individuals — particularly those with adverse baseline metabolic profiles, who showed significant reductions in total triglycerides and VLDL-lipid content.
No unpleasant garlic odor or taste
Pharmactive's proprietary aging process (controlled temperature and humidity Maillard reaction) eliminates the unpleasant garlic sensorial characteristics that limit compliance with raw garlic supplementation. Aged black garlic has a mild, sweet flavor without the pungent sulfur compounds responsible for garlic breath. Practical advantage for consumer compliance.
Mechanism of action
S-allyl cysteine (SAC) bioactivity
SAC is the most stable and bioavailable organosulfur compound in aged black garlic — widely studied for antioxidant and cardioprotective properties. SAC is generated during the controlled aging process from γ-glutamylcysteine precursors in raw garlic. Distinct from allicin (the active in fresh garlic) which is unstable and degraded quickly.
Nitric oxide pathway enhancement
ABG10+ supplementation enhances nitric oxide (NO) release in vascular endothelium. NO is a key vasodilator and cellular antioxidant — improving endothelial function, reducing peripheral resistance, and mitigating oxidative stress on blood vessels. Mechanism supports both BP reduction and broader vascular health.
ACE inhibition
ABG10+ reduces angiotensin-converting enzyme (ACE) activity, similar in mechanism to ACE inhibitor drugs but with milder magnitude. ACE converts angiotensin I to the potent vasoconstrictor angiotensin II — blocking this conversion lowers blood pressure. Provides natural modulation of the renin-angiotensin-aldosterone system (RAAS).
Antioxidant complex
ABG10+ contains a complex bioactive blend of antioxidants: polyphenols, flavonoids, melanoidins (generated during the Maillard reaction), and organosulfur compounds. The combined antioxidant capacity is greater than that of fresh garlic. Antioxidant activity mitigates oxidative damage to blood vessels and supports overall cardiovascular protection.
Lipoprotein subclass remodeling
NMR spectroscopy reveals ABG10+ induces specific qualitative changes in lipoprotein subclasses — particularly HDL functionality improvement (increased phospholipid, decreased triglyceride) and reduced cholesterol load in large VLDL particles. These qualitative changes may matter more for cardiovascular risk than simple total cholesterol numbers.
Clinical trials
Randomized, triple-blind, placebo-controlled parallel trial conducted at Hospital Universitari Arnau de Vilanova (Lleida, Spain) in collaboration with NUTREN-Nutrigenomics (University of Lleida) and the Atherothrombotic Disease Detection and Treatment Unit (UDETMA). Published in.
77 Grade-1 hypertension patients receiving prescribed antihypertensive drug therapy. 12-week intervention.
ABG10+ at 250 mg/day (0.25 mg SAC) over 12 weeks reduced systolic blood pressure by 1.8 mmHg and diastolic blood pressure by 1.5 mmHg vs placebo — effects observed on top of standard antihypertensive drug therapy. Secondary outcomes showed enhanced nitric oxide release and decreased ACE activity, supporting the proposed mechanism. Established ABG10+ as a complementary intervention in pharmaceutically-managed hypertension.
Randomized, crossover, double-blind, sustained and controlled trial evaluating ABG10+ for cardiovascular disease risk factors in moderately hypercholesterolemic subjects. Published in. Crossover design with washout period to control for individual variability.
Adults with moderately elevated cholesterol levels. Crossover protocol.
ABG10+ supplementation significantly reduced diastolic blood pressure by 5.85 mmHg on average vs placebo — larger BP effect than in the Grade-1 hypertension trial. Likely reflects greater opportunity for improvement in metabolically vulnerable populations. Established cardiovascular risk reduction beyond narrow blood pressure outcomes.
Sub-analysis of the Grade-1 hypertension clinical trial using NMR spectroscopy for detailed lipoprotein subclass and composition analysis. Published as medRxiv preprint 2026 (doi: 10.64898/2026.04.20.26351262v1). k-means clustering and PLS-DA analysis to identify responder subgroups.
75 Grade-1 hypertensive participants from the pivotal trial. 12-week intervention.
ABG supplementation reduced total particle number and HDL particle count. Detailed analysis showed XXL-VLDL particles had significant decrease in free and esterified cholesterol percentages. Large HDL particles exhibited beneficial remodeling (more phospholipid, less triglyceride). Cluster analysis identified that participants with adverse baseline metabolic profiles experienced significant triglyceride and VLDL-lipid reductions — suggesting personalized benefit patterns.